Renate B Schnabel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1038918/publications.pdf

Version: 2024-02-01

		7069	5364
299	30,793	78	164
papers	citations	h-index	g-index

324	324	324	35470
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet, The, 2015, 386, 154-162.	6.3	1,148
3	Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction. New England Journal of Medicine, 2009, 361, 868-877.	13.9	1,021
4	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, The, 2012, 379, 1214-1224.	6.3	886
5	Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet, The, 2009, 373, 739-745.	6.3	883
6	New loci associated with kidney function and chronic kidney disease. Nature Genetics, 2010, 42, 376-384.	9.4	710
7	Epidemiology of Atrial Fibrillation in the 21st Century. Circulation Research, 2020, 127, 4-20.	2.0	624
8	Cross-Sectional Relations of Digital Vascular Function to Cardiovascular Risk Factors in the Framingham Heart Study. Circulation, 2008, 117, 2467-2474.	1.6	607
9	Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGEâ€AF Consortium. Journal of the American Heart Association, 2013, 2, e000102.	1.6	601
10	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	6.3	562
11	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	9.4	552
12	Genetics and Beyond â€“ The Transcriptome of Human Monocytes and Disease Susceptibility. PLoS ONE, 2010, 5, e10693.	1.1	539
13	Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels. Circulation, 2011, 123, 731-738.	1.6	461
14	Screening for Atrial Fibrillation. Circulation, 2017, 135, 1851-1867.	1.6	453
15	Common variants in KCNN3 are associated with lone atrial fibrillation. Nature Genetics, 2010, 42, 240-244.	9.4	438
16	Genome-wide association study of PR interval. Nature Genetics, 2010, 42, 153-159.	9.4	400
17	Pericardial Fat Is Associated With Prevalent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 345-350.	2.1	364
18	Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nature Genetics, 2009, 41, 879-881.	9.4	363

#	Article	IF	Citations
19	A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. Cell, 2017, 170, 522-533.e15.	13.5	356
20	Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease. Circulation Research, 2005, 97, e53-9.	2.0	330
21	Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts. Circulation, 2010, 121, 2388-2397.	1.6	320
22	Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts. Circulation, 2017, 136, 1588-1597.	1.6	307
23	Genome-Wide Association Study for Coronary Artery Calcification With Follow-Up in Myocardial Infarction. Circulation, 2011, 124, 2855-2864.	1.6	269
24	Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community. Circulation, 2010, 121, 200-207.	1.6	243
25	Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nature Reviews Cardiology, 2016, 13, 321-332.	6.1	236
26	Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Human Molecular Genetics, 2010, 19, 1863-1872.	1.4	233
27	Genetic Analysis of the Interleukin-18 System Highlights the Role of the Interleukin-18 Gene in Cardiovascular Disease. Circulation, 2005, 112, 643-650.	1.6	205
28	Genetic Variants Associated With Cardiac Structure and Function. JAMA - Journal of the American Medical Association, 2009, 302, 168.	3.8	202
29	Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. European Heart Journal, 2016, 37, 2428-2437.	1.0	200
30	Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. European Heart Journal, 2008, 30, 813-819.	1.0	193
31	Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nature Genetics, 2011, 43, 940-947.	9.4	191
32	Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiology, 2016, 1, 397.	3.0	186
33	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
34	Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes. Diabetes Care, 2015, 38, 1356-1364.	4.3	177
35	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2009, 7, 49-57.	1.9	169
36	Noninvasive Vascular Function Measurement in the Community. Circulation: Cardiovascular Imaging, 2011, 4, 371-380.	1.3	167

#	Article	IF	Citations
37	Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. European Heart Journal, 2017, 38, 2490-2498.	1.0	161
38	High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. European Heart Journal, 2014, 35, 271-281.	1.0	160
39	miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease. PLoS ONE, 2015, 10, e0145930.	1.1	160
40	Long-Term Outcomes of Secondary Atrial Fibrillation in the Community. Circulation, 2015, 131, 1648-1655.	1.6	154
41	Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery diseaseâ€"results from the large AtheroGene study. European Heart Journal, 2016, 38, ehw250.	1.0	151
42	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014, 16, 1426-1433.	0.7	144
43	Relations of Inflammatory Biomarkers and Common Genetic Variants With Arterial Stiffness and Wave Reflection. Hypertension, 2008, 51, 1651-1657.	1.3	141
44	P Wave Duration and Risk of Longitudinal Atrial Fibrillation in Persons â‰¥60 Years Old (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	141
45	Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clinical Research in Cardiology, 2013, 102, 495-503.	1.5	138
46	Relation of Multiple Inflammatory Biomarkers to Incident Atrial Fibrillation. American Journal of Cardiology, 2009, 104, 92-96.	0.7	131
47	A Genome-Wide Association Study Identifies LIPA as a Susceptibility Gene for Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2011, 4, 403-412.	5.1	130
48	Integrating Genome-Wide Genetic Variations and Monocyte Expression Data Reveals Trans-Regulated Gene Modules in Humans. PLoS Genetics, 2011, 7, e1002367.	1.5	126
49	White Blood Cells and Blood Pressure. Circulation, 2020, 141, 1307-1317.	1.6	125
50	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	0.7	121
51	Validation of an Atrial Fibrillation Risk Algorithm in Whites and African Americans. Archives of Internal Medicine, 2010, 170, 1909-17.	4.3	120
52	Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. European Heart Journal, 2008, 29, 649-657.	1.0	117
53	Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2009, 2, 286-292.	5.1	113
54	Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood, 2010, 115, 5289-5299.	0.6	113

#	Article	IF	Citations
55	Genome-wide association with select biomarker traits in the Framingham Heart Study. BMC Medical Genetics, 2007, 8, S11.	2.1	111
56	High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. European Heart Journal, 2013, 34, 3563-3571.	1.0	110
57	Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A meta-analysis of adjusted observational results. International Journal of Cardiology, 2013, 168, 2528-2532.	0.8	108
58	Pleiotropic genes for metabolic syndrome and inflammation. Molecular Genetics and Metabolism, 2014, 112, 317-338.	0.5	107
59	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart, 2017, 103, 1024-1030.	1.2	104
60	Glutathione Peroxidase-1 and Homocysteine for Cardiovascular Risk Prediction. Journal of the American College of Cardiology, 2005, 45, 1631-1637.	1.2	103
61	Removing Batch Effects from Longitudinal Gene Expression - Quantile Normalization Plus ComBat as Best Approach for Microarray Transcriptome Data. PLoS ONE, 2016, 11, e0156594.	1.1	101
62	B-Type Natriuretic Peptide and the Risk of Cardiovascular Events and Death in Patients With Stable Angina. Journal of the American College of Cardiology, 2006, 47, 552-558.	1.2	99
63	Multiple marker approach to risk stratification in patients with stable coronary artery disease. European Heart Journal, 2010, 31, 3024-3031.	1.0	97
64	Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2793-2799.	1.1	96
65	Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. European Heart Journal, 2009, 30, 314-320.	1.0	96
66	Risk assessment for incident heart failure in individuals with atrial fibrillation. European Journal of Heart Failure, 2013, 15, 843-849.	2.9	96
67	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	0.7	95
68	Development of a risk score for outcome after transcatheter aortic valve implantation. Clinical Research in Cardiology, 2014, 103, 631-640.	1.5	92
69	Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis, 2007, 193, 121-128.	0.4	91
70	Gender differences and outcomes in left ventricular assist device support: The European Registry for Patients with Mechanical Circulatory Support. Journal of Heart and Lung Transplantation, 2018, 37, 61-70.	0.3	91
71	Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. European Heart Journal, 2005, 26, 241-249.	1.0	90
72	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Medicine, 2019, 16, e1002903.	3.9	90

#	Article	IF	Citations
73	Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes. Circulation Genomic and Precision Medicine, 2020, 13, e002872.	1.6	90
74	Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. European Heart Journal, 2012, 33, 238-251.	1.0	89
75	Genome-Wide Association Studies of the PR Interval in African Americans. PLoS Genetics, 2011, 7, e1001304.	1.5	88
76	Glutathione Peroxidase-1 Activity, Atherosclerotic Burden, and Cardiovascular Prognosis. American Journal of Cardiology, 2007, 99, 808-812.	0.7	86
77	Rationale and Design of the Hamburg City Health Study. European Journal of Epidemiology, 2020, 35, 169-181.	2.5	85
78	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
79	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European Heart Journal, 2022, 43, 1219-1230.	1.0	84
80	Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1728-1733.	1.1	83
81	BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. European Journal of Epidemiology, 2014, 29, 777-790.	2.5	83
82	Serum selenium and prognosis in cardiovascular disease: results from the AtheroGene study. Atherosclerosis, 2010, 209, 271-277.	0.4	81
83	Sex Differences in Early Carotid Atherosclerosis (from the Community-Based Gutenberg-Heart Study). American Journal of Cardiology, 2011, 107, 1841-1847.	0.7	81
84	Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease. American Heart Journal, 2008, 156, 1201.e1-1201.e11.	1.2	79
85	Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. European Heart Journal, 2021, 42, 1170-1177.	1.0	79
86	Atrial Fibrillation. Deutsches Ärzteblatt International, 2012, 109, 293-9.	0.6	79
87	Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans. European Heart Journal, 2015, 36, 3437-3446.	1.0	76
88	Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm. International Journal of Cardiology, 2009, 134, 33-41.	0.8	74
89	Large-Scale Candidate Gene Analysis in Whites and African Americans Identifies IL6R Polymorphism in Relation to Atrial Fibrillation. Circulation: Cardiovascular Genetics, 2011, 4, 557-564.	5.1	74
90	PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity. Nature Communications, 2018, 9, 2904.	5.8	71

#	Article	IF	Citations
91	Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. European Heart Journal, 2006, 27, 150-156.	1.0	69
92	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2007, 5, 475-482.	1.9	68
93	Oxidative Stress in Cardiovascular Disease. Circulation, 2007, 116, 1338-1340.	1.6	67
94	Transapical Implantation of a Second-Generation Transcatheter Heart Valve in Patients With Noncalcified Aortic Regurgitation. JACC: Cardiovascular Interventions, 2013, 6, 590-597.	1.1	66
95	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. Circulation, 2022, 145, 392-409.	1.6	65
96	Type D Personality as a Cardiovascular Risk Marker in the General Population: Results from the Gutenberg Health Study. Psychotherapy and Psychosomatics, 2012, 81, 108-117.	4.0	62
97	Atrial Fibrillation Patterns and Risks of Subsequent Stroke, Heart Failure, or Death in the Community. Journal of the American Heart Association, 2013, 2, e000126.	1.6	61
98	Direct measurement of left ventricular outflow tract by transthoracic real-time 3D-echocardiography increases accuracy in assessment of aortic valve stenosis. International Journal of Cardiology, 2009, 136, 64-71.	0.8	59
99	Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. European Heart Journal, 2006, 27, 2962-2968.	1.0	58
100	The Relation of Genetic and Environmental Factors to Systemic Inflammatory Biomarker Concentrations. Circulation: Cardiovascular Genetics, 2009, 2, 229-237.	5.1	58
101	Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I. Clinical Chemistry, 2017, 63, 394-402.	1.5	57
102	Atrial fibrillation in women: treatment. Nature Reviews Cardiology, 2017, 14, 113-124.	6.1	56
103	Next Steps in Cardiovascular Disease Genomic Researchâ€"Sequencing, Epigenetics, and Transcriptomics. Clinical Chemistry, 2012, 58, 113-126.	1.5	55
104	Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clinical Research in Cardiology, 2018, 107, 871-880.	1.5	55
105	Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe. JACC: Heart Failure, 2019, 7, 204-213.	1.9	54
106	Distribution and Categorization of Left Ventricular Measurements in the General Population. Circulation: Cardiovascular Imaging, 2010, 3, 604-613.	1.3	53
107	Insulin Resistance and Atrial Fibrillation (from the Framingham Heart Study). American Journal of Cardiology, 2012, 109, 87-90.	0.7	52
108	Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheterization and Cardiovascular Interventions, 2013, 82, 640-652.	0.7	52

#	Article	IF	Citations
109	Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. Lancet Neurology, The, 2021, 20, 426-436.	4.9	51
110	Clinical correlates of change in inflammatory biomarkers: TheÂFramingham Heart Study. Atherosclerosis, 2013, 228, 217-223.	0.4	50
111	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open, 2019, 9, e022478.	0.8	50
112	Biomarkers for characterization of heart failure â€“ Distinction of heart failure with preserved and reduced ejection fraction. International Journal of Cardiology, 2017, 227, 272-277.	0.8	49
113	Novel Loci Associated With PR Interval in a Genome-Wide Association Study of 10 African American Cohorts. Circulation: Cardiovascular Genetics, 2012, 5, 639-646.	5.1	48
114	Multiple Biomarkers and Atrial Fibrillation in the General Population. PLoS ONE, 2014, 9, e112486.	1.1	48
115	Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis, 2007, 195, e126-e134.	0.4	47
116	Predicting Risk in Transcatheter Aortic Valve Implantation: Comparative Analysis of EuroSCORE II and Established Risk Stratification Tools. Thoracic and Cardiovascular Surgeon, 2015, 63, 472-478.	0.4	47
117	Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovascular Research, 2022, 118, 2415-2427.	1.8	45
118	Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radical Biology and Medicine, 2007, 43, 1189-1196.	1.3	44
119	Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace, 2020, 22, 684-694.	0.7	44
120	Assessment of the Tricuspid Valve Morphology by Transthoracic Real-Time-3D-Echocardiography. Echocardiography, 2005, 22, 15-23.	0.3	43
121	Multiple Endothelial Biomarkers and Noninvasive Vascular Function in the General Population. Hypertension, 2012, 60, 288-295.	1.3	43
122	Midregional Proadrenomedullin for Prediction of Cardiovascular Events in Coronary Artery Disease: Results from the AtheroGene Study. Clinical Chemistry, 2012, 58, 226-236.	1.5	43
123	Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. International Journal of Cardiology, 2016, 218, 298-304.	0.8	43
124	Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2022, 43, 2442-2460.	1.0	43
125	Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis, 2013, 228, 451-459.	0.4	42
126	Cardiovascular risk factor distribution and subjective risk estimation in urban women â€“ The BEFRI Study: a randomized cross-sectional study. BMC Medicine, 2015, 13, 52.	2.3	42

#	Article	IF	Citations
127	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
128	Association of Serum Procalcitonin With Cardiovascular Prognosis in Coronary Artery Disease. Circulation Journal, 2011, 75, 1184-1191.	0.7	41
129	Differential Associations of Depressive Symptom Dimensions with Cardio-Vascular Disease in the Community: Results from the Gutenberg Health Study. PLoS ONE, 2013, 8, e72014.	1.1	41
130	NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke. Stroke, 2019, 50, 610-617.	1.0	41
131	Pâ€Wave Indices: Derivation of Reference Values from the Framingham Heart Study. Annals of Noninvasive Electrocardiology, 2010, 15, 344-352.	0.5	40
132	FEV1 and FVC predict all-cause mortality independent of cardiac function â€" Results from the population-based Gutenberg Health Study. International Journal of Cardiology, 2017, 234, 64-68.	0.8	40
133	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. Circulation, 2020, 141, 1915-1926.	1.6	40
134	Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome. Biomolecules, 2018, 8, 60.	1.8	39
135	Association of Circulating Metabolites With Risk of Coronary Heart Disease in a European Population. JAMA Cardiology, 2019, 4, 1270.	3.0	39
136	World Heart Federation Roadmap on Atrial Fibrillation â€" A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39
137	Depression in Atrial Fibrillation in the General Population. PLoS ONE, 2013, 8, e79109.	1.1	39
138	European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. European Stroke Journal, 2022, 7, CVII-CXXXIX.	2.7	39
139	Impact of Ancestry and Common Genetic Variants on QT Interval in African Americans. Circulation: Cardiovascular Genetics, 2012, 5, 647-655.	5.1	38
140	Fifteen Genetic Loci Associated With the Electrocardiographic P Wave. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	38
141	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. International Journal of Cardiology, 2018, 265, 141-147.	0.8	38
142	Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women â€" results from the FINRISK study. European Journal of Preventive Cardiology, 2018, 25, 1133-1139.	0.8	38
143	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. European Journal of Internal Medicine, 2020, 82, 97-104.	1.0	38
144	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	0.7	38

#	Article	IF	Citations
145	Fine-mapping, novel loci identification, and SNP association transferability in a genome-wide association study of QRS duration in African Americans. Human Molecular Genetics, 2016, 25, 4350-4368.	1.4	37
146	Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: Contemporary data from the INTERCATH cohort. Atherosclerosis, 2018, 275, 256-261.	0.4	36
147	Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study. Clinical Research in Cardiology, 2014, 103, 211-222.	1.5	35
148	Single-centre experience with next-generation devices for transapical aortic valve implantationâ€. European Journal of Cardio-thoracic Surgery, 2015, 47, 39-45.	0.6	35
149	Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis, 2009, 204, 601-607.	0.4	34
150	Blood transfusion is associated with impaired outcome after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2015, 85, 460-467.	0.7	34
151	Transcriptome-Wide Analysis Identifies Novel Associations With Blood Pressure. Hypertension, 2017, 70, 743-750.	1.3	34
152	Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population. European Journal of Preventive Cardiology, 2021, 28, 152-158.	0.8	34
153	Relations of Metabolically Healthy and Unhealthy Obesity to Digital Vascular Function in Three Communityâ€Based Cohorts: A Metaâ€Analysis. Journal of the American Heart Association, 2017, 6, .	1.6	32
154	Detection of Atrial Fibrillation in Cryptogenic Stroke. Current Neurology and Neuroscience Reports, 2018, 18, 66.	2.0	32
155	Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. Human Genetics, 2014, 133, 985-995.	1.8	31
156	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 226-236.	1.4	31
157	Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. Journal of Clinical Medicine, 2021, 10, 729.	1.0	30
158	Common genetic variation near the connexin-43 gene is associated with resting heart rate in African Americans: A genome-wide association study of 13,372 participants. Heart Rhythm, 2013, 10, 401-408.	0.3	29
159	Early diagnosis of acute myocardial infarction using high-sensitivity troponin I. PLoS ONE, 2017, 12, e0174288.	1.1	29
160	The imminent epidemic of atrial fibrillation and its concomitant diseases â€“ Myocardial infarction and heart failure - A cause for concern. International Journal of Cardiology, 2019, 287, 162-173.	0.8	29
161	Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain. Journal of the American Heart Association, 2016, 5, e002565.	1.6	28
162	Relations of Sex to Diagnosis and Outcomes in Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, .	1.6	28

#	Article	IF	Citations
163	The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. European Heart Journal, 2008, 29, 923-931.	1.0	27
164	Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	0.7	27
165	Challenging the 99th percentile: A lower troponin cutoff leads to low mortality of chest pain patients. International Journal of Cardiology, 2017, 232, 289-293.	0.8	27
166	Haplotypes of the Caspase-1 Gene, Plasma Caspase-1 Levels, and Cardiovascular Risk. Circulation Research, 2006, 99, 102-108.	2.0	26
167	Risk Factors of Coronary Artery Disease in Secondary Preventionâ€"Results from the AtheroGeneâ€"Study. PLoS ONE, 2015, 10, e0131434.	1.1	26
168	Relation between Arterial Stiffness and Markers of Inflammation and Hemostasis â€“ Data from the Population-based Gutenberg Health Study. Scientific Reports, 2017, 7, 6346.	1.6	26
169	The distribution of whole blood viscosity, its determinants and relationship with arterial blood pressure in the community: cross-sectional analysis from the Gutenberg Health Study. Therapeutic Advances in Cardiovascular Disease, 2015, 9, 354-365.	1.0	24
170	Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. Journal of the American Heart Association, 2018, 7, .	1.6	24
171	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. International Journal of Cardiology, 2018, 270, 160-166.	0.8	24
172	Heart and brain interactions. Herz, 2021, 46, 138-149.	0.4	24
173	Realâ€time optical coherence tomography coregistration with angiography in percutaneous coronary interventionâ€"impact on physician decisionâ€making: The OPTICOâ€integration study. Catheterization and Cardiovascular Interventions, 2018, 92, 30-37.	0.7	23
174	Iron Metabolism Contributes to Prognosis in Coronary Artery Disease: Prognostic Value of the Soluble Transferrin Receptor Within the AtheroGene Study. Journal of the American Heart Association, 2020, 9, e015480.	1.6	23
175	Applying the ESC 2016, H₂FPEF, and HFAâ€PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. ESC Heart Failure, 2021, 8, 3603-3612.	1.4	23
176	Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia. Human Molecular Genetics, 2013, 22, 3381-3393.	1.4	22
177	Molecular Characterization of the NLRC4 Expression in Relation to Interleukin-18 Levels. Circulation: Cardiovascular Genetics, 2015, 8, 717-726.	5.1	22
178	Functional Characterization of Rare Variants in the SHOX2 Gene Identified in Sinus Node Dysfunction and Atrial Fibrillation. Frontiers in Genetics, 2019, 10, 648.	1.1	21
179	Potential Impact of Oral Inflammations on Cardiac Functions and Atrial Fibrillation. Biomolecules, 2018, 8, 66.	1.8	20
180	Atrial fibrillation: villain or bystander in vascular brain injury. European Heart Journal Supplements, 2020, 22, M51-M59.	0.0	20

#	Article	IF	Citations
181	Age-specific atrial fibrillation incidence, attributable risk factors and risk of stroke and mortality: results from the MORGAM Consortium. Open Heart, 2021, 8, e001624.	0.9	20
182	Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovascular Diabetology, 2021, 20, 223.	2.7	20
183	A Common SCN5A Variant Is Associated with PR Interval and Atrial Fibrillation Among African Americans. Journal of Cardiovascular Electrophysiology, 2014, 25, 1150-1157.	0.8	19
184	ADMA, subclinical changes and atrial fibrillation in the general population. International Journal of Cardiology, 2016, 203, 640-646.	0.8	19
185	Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. International Journal of Cardiology, 2018, 257, 24-29.	0.8	19
186	Can We Predict the Occurrence of Atrial Fibrillation?. Clinical Cardiology, 2012, 35, 5-9.	0.7	18
187	Strategies to Design and Analyze Targeted Sequencing Data. Circulation: Cardiovascular Genetics, 2014, 7, 335-343.	5.1	18
188	Diversity 4.0 in the cardiovascular health-care workforce. Nature Reviews Cardiology, 2020, 17, 751-753.	6.1	18
189	Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study. BMC Medical Genetics, 2012, 13, 103.	2.1	17
190	Association of multiple biomarkers and classical risk factors with early carotid atherosclerosis: results from the Gutenberg Health Study. Clinical Research in Cardiology, 2014, 103, 477-485.	1.5	17
191	Prognostic Value of Iron-Homeostasis Regulating Peptide Hepcidin in Coronary Heart Diseaseâ€"Evidence from the Large AtheroGene Study. Biomolecules, 2018, 8, 43.	1.8	17
192	Sex differences in patients with cardiogenic shock. ESC Heart Failure, 2021, 8, 1775-1783.	1.4	17
193	Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Clinical Therapeutics, 2021, 43, 1583-1600.	1.1	17
194	Tissue-specific multi-omics analysis of atrial fibrillation. Nature Communications, 2022, 13, 441.	5.8	17
195	Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1125-33.	1.4	16
196	Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: results from the AtheroGene study. Biomarkers, 2017, 22, 210-218.	0.9	16
197	Cardiac imaging after ischemic stroke. Herz, 2019, 44, 296-303.	0.4	16
198	Upâ€andâ€Coming Markers: Myeloperoxidase, a Novel Biomarker Test for Heart Failure and Acute Coronary Syndrome Application?. Congestive Heart Failure, 2008, 14, 46-48.	2.0	15

#	Article	IF	Citations
199	Kidney injury and mortality after transcatheter aortic valve implantation in a routine clinical cohort. Catheterization and Cardiovascular Interventions, 2015, 85, 440-447.	0.7	15
200	Comparison of Cox Model Methods in A Low-dimensional Setting with Few Events. Genomics, Proteomics and Bioinformatics, 2016, 14, 235-243.	3.0	15
201	ADMA and arginine derivatives in relation to non-invasive vascular function in the general population. Atherosclerosis, 2016, 244, 149-156.	0.4	15
202	Opportunistic Electrocardiogram Screening for Atrial Fibrillation to Prevent Stroke. JAMA Cardiology, 2019, 4, 91.	3.0	15
203	Cognitive impairment in patients with atrial fibrillation: Implications for outcome in a cohort study. International Journal of Cardiology, 2021, 323, 83-89.	0.8	15
204	Risk prediction of atrial fibrillation in the community combining biomarkers and genetics. Europace, 2021, 23, 674-681.	0.7	15
205	KCND3 potassium channel gene variant confers susceptibility to electrocardiographic early repolarization pattern. JCI Insight, 2019, 4, .	2.3	15
206	Sex differences in noninvasive vascular function in the community. Journal of Hypertension, 2013, 31, 1437-1446.	0.3	14
207	High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 419-427.	0.4	14
208	Genome-Wide Association Analysis for Severity of Coronary Artery Disease Using the Gensini Scoring System. Frontiers in Cardiovascular Medicine, 2017, 4, 57.	1.1	14
209	Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart, 2018, 104, 1608-1614.	1.2	14
210	Intrinsic Iron Release Is Associated with Lower Mortality in Patients with Stable Coronary Artery Diseaseâ€"First Report on the Prospective Relevance of Intrinsic Iron Release. Biomolecules, 2018, 8, 72.	1.8	14
211	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. International Journal of Cardiology, 2019, 296, 65-70.	0.8	14
212	Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. Europace, 2020, 22, 1463-1469.	0.7	14
213	Cardioâ€Renal Biomarker Soluble Urokinaseâ€Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, Câ€Reactive Protein, and Renal Function. Journal of the American Heart Association, 2020, 9, e015452.	1.6	14
214	Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart, 2022, 108, 1873-1880.	1.2	14
215	Valve-in-valve implantation of a novel and small self-expandable transcatheter heart valve in degenerated small surgical bioprostheses: The Hamburg experience. Catheterization and Cardiovascular Interventions, 2014, 84, 486-493.	0.7	13
216	SYNTAX score-0 patients: risk stratification in nonobstructive coronary artery disease. Clinical Research in Cardiology, 2016, 105, 901-911.	1.5	13

#	Article	IF	Citations
217	Cardiovascular magnetic resonance imaging in the prospective, population-based, Hamburg City Health cohort study: objectives and design. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 68.	1.6	13
218	Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death. Journal of the American Heart Association, 2020, 9, e015218.	1.6	13
219	The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. European Journal of Preventive Cardiology, 2021, 28, 47-56.	0.8	13
220	ESC Working Group on e-Cardiology Position Paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients. European Heart Journal Digital Health, 2022, 3, 341-358.	0.7	13
221	A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. European Journal of Preventive Cardiology, 2012, 19, 874-884.	0.8	12
222	Atherosclerotic Biomarkers and Aortic Atherosclerosis by Cardiovascular Magnetic Resonance Imaging in the Framingham Heart Study. Journal of the American Heart Association, 2013, 2, e000307.	1.6	12
223	Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008197.	2.1	12
224	Expert opinion paper on cardiac imaging after ischemic stroke. Clinical Research in Cardiology, 2021, 110, 938-958.	1.5	12
225	Chronic kidney disease and risk of atrial fibrillation and heart failure in general populationâ€based cohorts: the BiomarCaRE project. ESC Heart Failure, 2022, 9, 57-65.	1.4	12
226	Periodontitis, dental plaque, and atrial fibrillation in the Hamburg City Health Study. PLoS ONE, 2021, 16, e0259652.	1.1	12
227	Activity of superoxide dismutase copper/zinc type and prognosis in a cohort of patients with coronary artery disease. Biomarkers in Medicine, 2015, 9, 597-604.	0.6	11
228	Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation. American Heart Journal, 2016, 176, 100-106.	1.2	11
229	Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. Clinical Research in Cardiology, 2017, 106, 401-410.	1.5	11
230	Homocysteine concentration in coronary artery disease: Influence of three common single nucleotide polymorphisms. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 168-175.	1.1	11
231	Noninvasive peripheral vascular function and atrial fibrillation in the general population. Journal of Hypertension, 2019, 37, 928-934.	0.3	11
232	Left ventricular geometry and function in early repolarization: results from the population-based Gutenberg Health Study. Clinical Research in Cardiology, 2019, 108, 1107-1116.	1.5	11
233	Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality. Europace, 2020, 22, 522-529.	0.7	11
234	Genetics of atrial fibrillationâ€”practical applications for clinical management: if not now, when and how?. Cardiovascular Research, 2021, 117, 1718-1731.	1.8	11

#	Article	IF	Citations
235	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006852.	0.9	11
236	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. Journal of the American Heart Association, 2022, 11, e022833.	1.6	11
237	Machine learning-based identification of risk-factor signatures for undiagnosed atrial fibrillation in primary prevention and post-stroke in clinical practice. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 16-23.	1.8	11
238	The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease. Biomarkers in Medicine, 2015, 9, 731-741.	0.6	10
239	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical Therapeutics, 2017, 39, 2311-2320.e2.	1.1	10
240	Stroke subtype classification by geometrical descriptors of lesion shape. PLoS ONE, 2017, 12, e0185063.	1.1	10
241	Atrial Fibrillation Manifestations Risk Factors and Sex Differences in a Population-Based Cohort (From the Gutenberg Health Study). American Journal of Cardiology, 2018, 122, 76-82.	0.7	10
242	Cardiac Troponin I and Incident Stroke in European Cohorts. Stroke, 2020, 51, 2770-2777.	1.0	9
243	Head-to-Head Comparison of the Incremental Predictive Value of The Three Established Risk Markers, Hs-troponin I, C-Reactive Protein, and NT-proBNP, in Coronary Artery Disease. Biomolecules, 2020, 10, 394.	1.8	9
244	Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network. International Journal of Cardiology, 2021, 331, 57-62.	0.8	9
245	Treatment-Relevant Findings in Transesophageal Echocardiography After Stroke: A Prospective Multicenter Cohort Study. Stroke, 2022, 53, 177-184.	1.0	9
246	Upâ€andâ€Coming Markers: Myeloperoxidase, a Novel Biomarker Test for Heart Failure and Acute Coronary Syndrome Application?. Congestive Heart Failure, 2008, 14, 46-48.	2.0	8
247	Cross-Sectional Associations between Homoarginine, Intermediate Phenotypes, and Atrial Fibrillation in the Communityâ€"The Gutenberg Health Study. Biomolecules, 2018, 8, 86.	1.8	8
248	Association between periodontitis and metabolic syndrome in the Hamburg City Health Study. Journal of Periodontology, 2022, 93, 1150-1160.	1.7	8
249	Risk Factors, Subsequent Disease Onset, and Prognostic Impact of Myocardial Infarction and Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, e024299.	1.6	8
250	Crossâ€sectional analysis of the association of periodontitis with carotid intima media thickness and atherosclerotic plaque in the Hamburg City health study. Journal of Periodontal Research, 0, , .	1.4	8
251	Digital, risk-based screening for atrial fibrillation in the European communityâ€"the AFFECT-EU project funded by the European Union. European Heart Journal, 2021, 42, 2625-2627.	1.0	7
252	Candidate biomarkers in heart failure with reduced and preserved ejection fraction. Biomarkers, 2015, 20, 258-265.	0.9	6

#	Article	IF	Citations
253	The predictive value of different equations for estimation of glomerular filtration rate in patients with coronary artery disease â€" Results from the AtheroGene study. International Journal of Cardiology, 2016, 221, 908-913.	0.8	6
254	Underrepresentation of sex in reporting traditional and emerging biomarkers for primary prevention of cardiovascular disease: a systematic review. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 99-107.	1.8	6
255	Response by Magnussen et al to Letter Regarding Article, â€œSex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)â€. Circulation, 2018, 137, 2087-2088.	1.6	6
256	Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. Biomarkers in Medicine, 2016, 10, 95-106.	0.6	5
257	The Changing Landscape of AtrialÂFibrillation. JACC: Heart Failure, 2017, 5, 561-564.	1.9	5
258	Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS. Herz, 2018, 43, 20-25.	0.4	5
259	Sex differences in preformed panelâ€reactive antibody levels and outcomes in patients undergoing heart transplantation. Clinical Transplantation, 2019, 33, e13572.	0.8	5
260	No impact of sex and age on betaâ€adrenoceptorâ€mediated inotropy in human right atrial trabeculae. Acta Physiologica, 2021, 231, e13564.	1.8	5
261	Genetics, atrial cardiomyopathy, and stroke: enough components for a sufficient cause?. European Heart Journal, 2021, 42, 4533-4535.	1.0	5
262	Refined atrial fibrillation screening and cost-effectiveness in the German population. Heart, 2021, , heartjnl-2020-318882.	1.2	5
263	Patient gender does not affect outcome after transcatheter aortic valve implantation (TAVI). Journal of Heart Valve Disease, 2013, 22, 789-93.	0.5	5
264	The Relationship Between Vitamin D and Postoperative Atrial Fibrillation: A Prospective Cohort Study. Frontiers in Nutrition, 0, 9, .	1.6	5
265	Predicting the future in patients with atrial fibrillation: who develops heart failure?. European Journal of Heart Failure, 2013, 15, 366-367.	2.9	4
266	Sex Differences in Correlates of Intermediate Phenotypes and Prevalent Cardiovascular Disease in the General Population. Frontiers in Cardiovascular Medicine, 2015, 2, 15.	1.1	4
267	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. Internal and Emergency Medicine, 2021, 16, 591-599.	1.0	4
268	Impact of age on reperfusion success and long-term prognosis in ST-segment elevation myocardial infarction â€" A cardiac magnetic resonance imaging study. IJC Heart and Vasculature, 2021, 33, 100731.	0.6	4
269	Gender differences in characteristics and outcomes in heart failure patients referred for endâ€stage treatment. ESC Heart Failure, 2021, , .	1.4	4
270	Polygenic Risk Scores for Predicting Adverse Outcomes After Coronary Revascularization. American Journal of Cardiology, 2022, 167, 9-14.	0.7	4

#	Article	IF	Citations
271	Commentary: Circulating cytokines and risk stratification of stroke incidence--will we do better in future?. International Journal of Epidemiology, 2009, 38, 261-262.	0.9	3
272	Common Genetic Variation of Blood Pressure Traits and Their Relation to End-Organ Damage. Circulation: Cardiovascular Genetics, 2011, 4, 712-713.	5.1	3
273	Is It All Determined at Menarche?. Circulation, 2015, 131, 227-229.	1.6	3
274	Sex and Stroke Risk in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 615-617.	1.3	3
275	Non-invasive peripheral vascular function, incident cardiovascular disease, and mortality in the general population. Cardiovascular Research, 2022, 118, 904-912.	1.8	3
276	The Association of Periodontitis and Peripheral Arterial Occlusive Disease in a Prospective Population-Based Cross-Sectional Cohort Study. Journal of Clinical Medicine, 2021, 10, 2048.	1.0	3
277	Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2022, 111, 416-427.	1.5	3
278	Remote Design of a Smartphone and Wearable Detected Atrial Arrhythmia in Older Adults Case Finding Study: Smart in OAC â€“ AFNET 9. Frontiers in Cardiovascular Medicine, 2022, 9, 839202.	1.1	3
279	Feasible approaches and implementation challenges to atrial fibrillation screening: a qualitative study of stakeholder views in 11 European countries. BMJ Open, 2022, 12, e059156.	0.8	3
280	Predicting atrial fibrillation â€“ Authors' reply. Lancet, The, 2009, 373, 1523-1524.	6.3	2
281	Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. Canadian Journal of Cardiology, 2016, 32, 1470-1477.	0.8	2
282	Common Genetic Variation in Relation to Brachial Vascular Dimensions and Flow-Mediated Vasodilation. Circulation Genomic and Precision Medicine, 2019, 12, e002409.	1.6	2
283	Integrated care in stroke survivors: When and how much?. EClinicalMedicine, 2020, 25, 100489.	3.2	2
284	Blunted beta-adrenoceptor-mediated inotropy in valvular cardiomyopathy: another piece of the puzzle in human aortic valve disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 56-63.	0.6	2
285	Mobile health for walking on the tightrope of optimal physical activity to reduce the risk of atrial fibrillation. European Heart Journal, 2021, 42, 2484-2486.	1.0	2
286	Differential association of flow velocities in the carotid artery with plaques, intima media thickness and cardiac function. Atherosclerosis Plus, 2021, 43, 18-23.	0.3	2
287	Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emeryâ€“Dreifuss Muscular Dystrophies: A Systematic Review of the Literature. Biology, 2022, 11, 530.	1.3	2
288	Comparison of Approaches to Fine-Map First-Generation Genome-Wide Association Study Results at Chromosome 9p21. Circulation: Cardiovascular Genetics, 2011, 4, 577-578.	5.1	1

#	Article	IF	Citations
289	Genome-Wide Genetic Association Study Meets Systematic Metabolite Screening. Circulation: Cardiovascular Genetics, 2012, 5, 479-480.	5.1	1
290	TCT-782 Single-center experience using three different second generation devices for transapical transcatheter aortic valve implantation. Journal of the American College of Cardiology, 2013, 62, B238.	1.2	1
291	Gender Differences in Clinical Characteristics and Outcomes in Patients Undergoing Heart Transplantation. Journal of Heart and Lung Transplantation, 2017, 36, S233.	0.3	1
292	Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110211.	0.7	1
293	Alcohol and atrial fibrillation: dose matters, not so much the type. European Heart Journal, 2021, 42, 2507-2508.	1.0	1
294	Adding to the evidence or to the confusion: dual antithrombotic therapy in chronic coronary syndrome and atrial fibrillation. Heart, 2021, 107, heartjnl-2021-319830.	1.2	1
295	Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2021, 10, 5130.	1.0	1
296	Performance of an electronic health record-based predictive model to identify patients with atrial fibrillation across countries. PLoS ONE, 2022, 17, e0269867.	1.1	1
297	Improving the Prediction of Incident Atrial Fibrillationâ€”Reply. Archives of Internal Medicine, 2011, 171, 1125.	4.3	0
298	Poor adherence to Mediterranean diet is independently associated with the severity of coronary artery disease-contemporary data from the INTERCATH study. Atherosclerosis, 2017, 263, e169.	0.4	0
299	Sex Differences in Prevalent Cardiovascular Disease in the General Population. Cardiac and Vascular Biology, 2019, , 381-406.	0.2	0